Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Health Misinformation and the Power of Narrative Messaging in the Public Sphere
Murdoch, Blake , Brown, Jasmine M., Perrault, Sarah Tinker, Jarry, Jonathan, Anthony, Samantha J. , Ogbogu, Ubaka , Greenberg, Joshua , Zarzeczny, Amy , Hyde-Lay, Robyn, Caulfield, Timothy , Marcon, Alessandro R , Snyder, Jeremy , Brooks, Stephanie P. , Master, Zubin , Rachul, Christen M.

Mayo Clinic

Canadian Journal of Bioethics | June 18, 2019 | Volume: 2 | Issue: 2 | Pages: 52-60

10.7202/1060911ar Get It

Numerous social, economic and academic pressures can have a negative impact on representations of biomedical research. We review several of the forces playing an increasingly pernicious role in how health and science information is interpreted, shared and used, drawing discussions towards the role of narrative. In turn, we explore how aspects of narrative are used in different social contexts and communication environments, and present creative responses that may help counter the negative trends. As traditional methods of communication have in many ways failed the public, changes in approach are required, including the creative use of narratives.
PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Stadtmauer, E., Monohan, Gregory, Kovacsovics, Tibor , Burwick, Nicholas , Jakubowiak, Andrzej , Hong, Wen-De, Freise, Kevin J. , Munasinghe, Wijith, Gudipati, Swapna, Mudd, S. Harvey, Bueno, Orlando F. , Kumar, Sathish , Costa, Luciano J. , Davies, Faith E. , Kaufman, Jonathan L. , Hong, W.‐J., Ross, Jeremy A. , Pesko, John Carl , Mudd, S.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 629

10.1097/01.hs9.0000563776.65272.b6 Get It

Background:Venetoclax (Ven) is a highly selective, potent, oral BCL‐2 inhibitor that induces apoptosis in malignant cells dependent on BCL‐2 for survival. Proteasome inhibitors (PIs) and dexamethasone (d) were shown to increase BCL‐2 dependence in multiple myeloma (MM) cells, and preclinical studies showed enhanced inhibition of MM tumor growth with Ven+PI compared to either alone. Moreover, d has been shown to indirectly promote BCL‐2 dependency in MM cells. Clinical trials have since demonstrated efficacy of Ven in combination with the PI bortezomib in patients (pts) with relapsed/refractory MM (RRMM).Aims:We report interim data for Ven combined with second‐generation PI carfilzomib (K) and d in pts with RRMM.Methods:In this ongoing Phase 2 study (NCT02899052), pts with RRMM (1–3 prior lines of therapy) and no prior K exposure received VenKd on 28‐day cycles in 4 dose‐finding and 1 expansion cohort: Ven 400 mg/day + K 27 mg/m2 Day 1, 2, 8, 9, 15, 16 + d 40 mg Day 1, 8, 15, 22 (Cohort 1); same regimen but with Ven 800 mg/day (Cohort 2); Ven 800 mg/day + K 70 mg/m2 Day 1, 8, 15 + d 40 mg Day 1, 8, 15, 22 (Cohort 3/expansion cohort); or Ven 800 mg + K 56 mg/m2 Day 1, 2, 8, 9, 15, 16 + d 40 mg Day 1, 2, 8, 9, 15, 16, 22, 23 (Cohort 4). Treatment continued until progressive disease or unacceptable toxicity.Results:As of the clinical data cut‐off of 1 Feb 2019, 43 pts were enrolled. Median age was 67 (range, 37–79), 26 (62%) pts had ISS II/III disease, and 8 (19%) were t (11;14)+. Median number of prior lines of therapy was 2 (range, 1–3). Forty (93%) pts received prior PI (49% refractory), 33 (77%) received prior immunomodulatory drug (IMiD, 61% refractory), and 33 (77%) received prior PI+IMiD (33% double refractory).All pts had at least 1 adverse event (AE). The most common AEs of any grade were diarrhea (65%), nausea (49%), fatigue (47%), cough (35%), insomnia, dyspnea, vomiting, upper respiratory infection (33% each), lymphopenia (28%), thrombocytopenia, and dyspepsia (26% each). Thirty‐six (84%) pts had a Grade 3/4 AE, the most common being lymphopenia (23%), pneumonia, hypertension (16% each), and hypophosphatemia (12%).The overall response rate (ORR) was 79%, complete response or better (≥CR) rate was 40%, and very good partial response or better (≥VGPR) rate was 64% for all pts (Table). Median follow‐up for 42 pts was 10.4 months (95% CI = 8.0–13.8); 15 pts had progression‐free survival (PFS) events, with median PFS yet to be achieved. Baseline bone marrow core biopsy samples from 25 pts were evaluated for BCL‐2 expression by immunohistochemistry, with high expression (≥50% of tumor cells with moderate or higher cytoplasmic staining) seen in 23 (92%) samples. Pts with high BCL‐2 expression had response rates similar to the overall study population. Other correlative biomarker analyses are ongoing.Summary/Conclusion:The combination of VenKd was found to be tolerable with no new safety signals. VenKd demonstrates promising efficacy in pts with RRMM. The study remains ongoing with an additional 60 pts with RRMM enrolling to assess efficacy and safety in a larger group of pts with similar eligibility (Cohort 6) and t (11;14)+ pts (Cohort 7).image
Interfascicular Resection of Benign Peripheral Nerve Sheath Tumors
Stone, Jonathan J. , Puffer, Ross C. , Spinner, Robert J.

Mayo Clinic

JBJS Essential Surgical Techniques | June 17, 2019 | Volume: 9 | Issue: 2 | Pages: e18

10.2106/jbjs.st.18.00077 | PMID 31579536 Get It

Background: Interfascicular resection is a surgical technique used to safely treat benign peripheral nerve sheath tumors through careful dissection of functional neural elements off the tumor surface 1,2 . Description: Proper operative technique is essential to improving symptoms, preserving neurologic function, and minimizing the chance for recurrence. Accurate tumor localization, ideal patient positioning, and placement of a longitudinal incision permit adequate exposure. Prior to tumor resection, normal nerve should be identified proximally and distally and controlled with vessel loops. This allows functional fascicles streaming around the tumor in the pseudocapsule to be visualized during resection. A fascicle-free window is identified on the tumor surface through visual inspection and intraoperative neurophysiology monitoring if desired. The pseudocapsule layers are divided with a sharp instrument until a smooth and shiny true capsule layer is found. This plane should have minimal resistance and is developed circumferentially until the tumor can be enucleated in toto. At the poles of the tumor, a single nonfunctional nerve fascicle that courses into the tumor is typically found. If there is >1 fascicle running into the tumor, further pseudocapsule layers should be undermined to sweep fascicles off the true capsule surface. The entering-exiting fascicle can be tested for function and is cut sharply. The specimen should be sent to pathology for permanent sectioning. The sides of the pseudocapsule are spread in opposite directions to evaluate for residual tumor, and any remaining tumor is removed if it can be done safely. Meticulous hemostasis is achieved, and the surgical site is closed in anatomical layers. Alternatives: Pain is the most common presenting symptom, and neuroleptic medications should be used in escalating dosage prior to surgical intervention. Nonoperative medical therapy does not typically result in symptom freedom, and patients often opt for resection. For tumors that are suspected of being malignant, an image-guided percutaneous or open biopsy and staging (positron emission tomography and/or computed tomography scans of the chest, abdomen, and pelvis) are recommended prior to treatment planning. For symptomatic benign extremity lesions, surgical resection is the treatment of choice, and adjuvant therapies like radiation and/or chemotherapy are not recommended. For malignant lesions, more aggressive surgery (wide resection or amputation) and preoperative, intraoperative, or postoperative radiation with or without chemotherapy are often utilized. Rationale: The treatment approach depends on a variety of presenting features such as onset, progression, symptom severity, tumor size, location, imaging features, presence of a syndrome, and patient age. There is little benefit from the resection of an incidentally found, small, nongrowing lesion. The most common reasons for removal of extremity lesions are a painful mass and/or radiating “nerve” pain. There is a high likelihood of relieving the symptoms and minimizing the risk of recurrence, and a relatively low risk of causing neurologic injury. The procedure provides a definitive diagnosis. For patients with severe pain, progressive weakness, rapid tumor growth, or concerning imaging characteristics, biopsy should be considered to determine malignant potential.
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP
Nowakowski, Grzegorz S. , Macon, Rita E., King, Rebecca L. , Wagner‐Johnston, Nina, Wade, James L. , Nagargoje, Gauri G., Reynolds, Christopher M. , Cohen, Jonathon B. , Amengual, Jennifer E. , Richards, Kristy L. , Little, Richard F. , Leonard, John P. , Friedberg, Jonathan W. , Kostakoglu, Lale , Kahl, Bradley, Hong, Fangxin , Scott, David W. , Habermann, Thomas M. , Casulo, Carla , Khan, Niloufer , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 37-38

10.1002/hon.6_2629 Get It

Big Data Approaches to Phenotyping Acute Ischemic Stroke Using Automated Lesion Segmentation of Multi-Center Magnetic Resonance Imaging Data
Wu, Ona , Winzeck, Stefan , Hancock, Brandon L., Etherton, Mark R. , Bouts, Mark J.R.J. , Donahue, Kathleen, Schirmer, Markus D. , Irie, Robert E., Mocking, Steven J. T. , McIntosh, Elissa C. , Bezerra, Raquel , Kamnitsas, Konstantinos , Frid, Petrea , Wassélius, Johan , Xu, Huichun , Jiménez-Conde, Jordi , Lorentzen, Eric, McArdle, Patrick F. , Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Stanne, Tara M. , Thijs, Vincent , Woo, Daniel , Kittner, Steven J. , Worrall, Bradford B. , Maguire, Jane , Rost, Natalia S. , Investigators, on behalf of the MRI-GENIE and GISCOME, Wu, Ona , Giese, Anne‐Katrin , Cole, John W. , Holmegaard, Lukas , Lemmens, Robin , Meschia, James F. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Vagal, Achala , Bevan, Steve , Mitchell, Braxton D. , Rosand, Jonathan M. , Jern, Christina , Lindgren, Arne G. , Investigators, on behalf of the MRI-GENIE and GISCOME

Mayo Clinic

Stroke | June 10, 2019 | Volume: 50 | Issue: 7 | Pages: 1734-1741

10.1161/strokeaha.119.025373 | PMID 31177973 Get It

Background and Purpose— We evaluated deep learning algorithms’ segmentation of acute ischemic lesions on heterogeneous multi-center clinical diffusion-weighted magnetic resonance imaging (MRI) data sets and explored the potential role of this tool for phenotyping acute ischemic stroke. Methods— Ischemic stroke data sets from the MRI-GENIE (MRI-Genetics Interface Exploration) repository consisting of 12 international genetic research centers were retrospectively analyzed using an automated deep learning segmentation algorithm consisting of an ensemble of 3-dimensional convolutional neural networks. Three ensembles were trained using data from the following: (1) 267 patients from an independent single-center cohort, (2) 267 patients from MRI-GENIE, and (3) mixture of (1) and (2). The algorithms’ performances were compared against manual outlines from a separate 383 patient subset from MRI-GENIE. Univariable and multivariable logistic regression with respect to demographics, stroke subtypes, and vascular risk factors were performed to identify phenotypes associated with large acute diffusion-weighted MRI volumes and greater stroke severity in 2770 MRI-GENIE patients. Stroke topography was investigated. Results— The ensemble consisting of a mixture of MRI-GENIE and single-center convolutional neural networks performed best. Subset analysis comparing automated and manual lesion volumes in 383 patients found excellent correlation (ρ=0.92; P <0.0001). Median (interquartile range) diffusion-weighted MRI lesion volumes from 2770 patients were 3.7 cm 3 (0.9–16.6 cm 3 ). Patients with small artery occlusion stroke subtype had smaller lesion volumes ( P <0.0001) and different topography compared with other stroke subtypes. Conclusions— Automated accurate clinical diffusion-weighted MRI lesion segmentation using deep learning algorithms trained with multi-center and diverse data is feasible. Both lesion volume and topography can provide insight into stroke subtypes with sufficient sample size from big heterogeneous multi-center clinical imaging phenotype data sets.
Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
Casey, Dana L. , Donaldson, Sarah S. , Hawkins, Douglas S. , Tian, Jing , Arndt, Carola A.S., Rodeberg, David A. , Gupta, Abha A. , Yock, Torunn I. , Hawkins, Douglas S , Arndt, Carola A., Gupta, Abha A , Donaldson, Sarah S , Casey, Dana L , Chi, Yueh‐Yun , Routh, Jonathan C. , Lautz, Timothy B. , Wolden, Suzanne L.

Mayo Clinic

Cancer | June 7, 2019 | Volume: 125 | Issue: 18 | Pages: 3242-3248

10.1002/cncr.32204 | PMID 31174239 Get It

Background The objective of this study was to evaluate local control for patients with intermediate‐risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531. Methods This study analyzed 424 patients with intermediate‐risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate‐risk study, D9803. Results For patients with group I/II alveolar RMS (n = 55), the 5‐year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% ( P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 ( P = .02). After adjustments for clinical prognostic factors, event‐free survival and overall survival were worse on ARST0531 ( P = .004 and P = .05, respectively). Conclusions Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.
Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
Chen, Qin , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Haley, Dana , Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Kraft, Ruth, Rademakers, Rosa , Rosen, Howie, Boxer, Adam L. , Kantarci, Kejal , Lesnick, Timothy, Kantarci, Kejal , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Journal of Neuroimaging | June 7, 2019 | Volume: 29 | Issue: 5 | Pages: 624-629

10.1111/jon.12642 | PMID 31173437 Get It

ABSTRACT BACKGROUND AND PURPOSE The objective of this study was to longitudinally investigate the trajectory of change in 1 H MRS measurements in asymptomatic MAPT mutation carriers who became symptomatic during follow‐up, and to determine the time at which the neurochemical alterations accelerated during disease progression. METHODS We identified eight MAPT mutations carriers who transitioned from asymptomatic to symptomatic disease during follow‐up. All participants were longitudinally followed with an average of 7.75 years (range 4‐11 years) and underwent two or more single voxel 1 H MRS examinations from the posterior cingulate voxel, with a total of 60 examinations. The rate of longitudinal change for each metabolite was estimated using linear mixed models. A flex point model was used to estimate the flex time point of the change in slope. RESULTS The decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline. A similar trajectory was observed in the presumed glial marker mI/Cr ratio accelerating 1.86 years prior to symptom onset. CONCLUSIONS Our findings support the potential use of longitudinal 1 H MRS for monitoring the neurodegenerative progression in MAPT mutation carriers starting from the asymptomatic stage.
Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
Yang, Hayang , Veldtman, Gruschen , Bouma, Berto J. , Budts, Werner , Niwa, Koichiro , Meijboom, Folkert J., Egbe, Alexander C. , Schwerzmann, Markus , Broberg, Craig S. , Buber, Jonathan , Tsai, Shane, Post, Martijn C. , Mulder, Barbara J.M. , Egbe, Alexander Chima, Schwerzmann, Markus , Scognamiglio, Giancarlo , Morissens, Marielle , Polyzois, Ioannis , Greutmann, Matthias , Dijk, Arie P.J. van , Aboulhosn, Jamil , Bouma, Berto J

Mayo Clinic

Open Heart | June 4, 2019 | Volume: 6 | Issue: 1 | Pages: e000985

10.1136/openhrt-2018-000985 | PMID 31245011 Get It

Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to evidence of harm. To address this gap in data, we investigated the safety and efficacy of NOACs in adults with a Fontan circulation in a worldwide study. Methods This is an international multicentre prospective cohort study, using data from the NOTE ( n on-vitamin K antagonist o ral anticoagulants for t hrombo e mbolic prevention in patients with congenital heart disease) registry. The study population comprised consecutive adults with a Fontan circulation using NOACs. Follow-up took place at 6 months and yearly thereafter. The primary endpoints were thromboembolism and major bleeding. Secondary endpoint was minor bleeding. Results From April 2014 onward, 74 patients (mean age 32±10 years (range 18–68), 54% male) with a Fontan circulation using NOACs were included. During a median follow-up of 1.2 (IQR 0.8–2.0) years, three thromboembolic events (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) and three major bleedings (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) occurred in five atriopulmonary Fontan and one total cavopulmonary connection Fontan patients with AA. Fifteen patients experienced minor bleeding episodes (15.8 per 100 patient-years (95% CI 9.1 to 25.2)). In patients (n=37) using vitamin K antagonists (VKAs) prior to the initiation of NOAC, annual incidence of historical thromboembolic events and major bleeding were 2.4% (95% CI 0.4% to 7.4%) (n = 2) and 1.2% (95% CI 0.7% to 5.1%) (n = 1), respectively. Conclusions In this review of the largest Fontan cohort using NOACs with prospective follow-up, NOACs appear to be well tolerated and their efficacy and safety during short-term follow-up seem comparable to VKAs. Longer term data are required to confirm these promising short-term results.